200 related articles for article (PubMed ID: 34827570)
1. Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing.
Van Hemelryk A; Mout L; Erkens-Schulze S; French PJ; van Weerden WM; van Royen ME
Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827570
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Efficacy of Anti-Cancer Drugs on Organoid Models Derived from Prostate Cancer.
Silkina MO; Razumovskaya AV; Nikulin SV; Tonevitsky AG; Alekseev BY
Dokl Biochem Biophys; 2023 Dec; 513(Suppl 1):S96-S99. PubMed ID: 38337100
[TBL] [Abstract][Full Text] [Related]
5. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
7. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
8. Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.
Van Hemelryk A; Erkens-Schulze S; Lim L; de Ridder CMA; Stuurman DC; Jenster GW; van Royen ME; van Weerden WM
Cells; 2023 May; 12(10):. PubMed ID: 37408211
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
10. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
[TBL] [Abstract][Full Text] [Related]
11. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
Choo N; Ramm S; Luu J; Winter JM; Selth LA; Dwyer AR; Frydenberg M; Grummet J; Sandhu S; Hickey TE; Tilley WD; Taylor RA; Risbridger GP; Lawrence MG; Simpson KJ
SLAS Discov; 2021 Oct; 26(9):1107-1124. PubMed ID: 34111999
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction.
Buelens S; Claeys T; Dhondt B; Poelaert F; Vynck M; Yigit N; Thas O; Ost P; Vandesompele J; Lumen N; Kumps C
Clin Genitourin Cancer; 2018 Jun; 16(3):197-205.e5. PubMed ID: 29366632
[TBL] [Abstract][Full Text] [Related]
16. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
[TBL] [Abstract][Full Text] [Related]
18. Non-matrigel scaffolds for organoid cultures.
Kaur S; Kaur I; Rawal P; Tripathi DM; Vasudevan A
Cancer Lett; 2021 Apr; 504():58-66. PubMed ID: 33582211
[TBL] [Abstract][Full Text] [Related]
19. AR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese C; Santoni M; Brunelli M; Buti S; Modena A; Nabissi M; Artibani W; Martignoni G; Montironi R; Tortora G; Massari F
Cancer Treat Rev; 2016 Feb; 43():27-35. PubMed ID: 26827690
[TBL] [Abstract][Full Text] [Related]
20. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]